Paul A Yates1, Patricia M Desmond, Pramit M Phal, Christopher Steward, Cassandra Szoeke, Olivier Salvado, Kathryn A Ellis, Ralph N Martins, Colin L Masters, David Ames, Victor L Villemagne, Christopher C Rowe. 1. From the Department of Nuclear Medicine and Centre for PET (P.A.Y., V.L.V., C.C.R.), Austin Health, Heidelberg; The University of Melbourne (P.A.Y., P.M.D., C.S., C.C.R.), Parkville; Department of Radiology (P.M.D., P.M.P., C.S.), Royal Melbourne Hospital, Parkville; National Ageing Research Institute (D.A.), Parkville; CSIRO Preventative Health Flagship (O.S.), Parkville; Florey Institute of Neuroscience and Mental Health (K.A.E., C.L.M., V.L.V.), The University of Melbourne, Parkville; Academic Unit for Psychiatry of Old Age (K.A.E., D.A.), Department of Psychiatry, The University of Melbourne, Kew, Victoria; Centre of Excellence for Alzheimer's Disease Research and Care (R.N.M.), School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Australia.
Abstract
OBJECTIVE: We sought to determine the incidence and associations of lobar microbleeds (LMBs) in a longitudinal cohort with (11)C-Pittsburgh compound B (PiB) PET imaging. METHODS: One hundred seventy-four participants from the observational Australian Imaging, Biomarkers and Lifestyle Study of Ageing (97 with normal cognition [NC], 37 with mild cognitive impairment [MCI], and 40 with Alzheimer disease [AD] dementia) were assessed at 3 time points over 3 years with 3-tesla susceptibility-weighted MRI and (11)C-PiB PET. MRIs were inspected for microbleeds, siderosis, infarction, and white matter hyperintensity severity, blind to clinical and PiB findings. Neocortical PiB standardized uptake value ratio, normalized to cerebellar cortex, was dichotomized as positive or negative (PiB+/-, standardized uptake value ratio >1.5). Annualized LMB incidence was calculated, and logistic regression was used to determine the association of incident LMBs with PiB, APOE ε4+ status, and cerebrovascular disease. RESULTS: LMBs were present in 18.6% of NC, 24.3% of MCI, and 40% of AD participants (p < 0.05 vs NC). LMB incidence was 0.2 ± 0.6 per year in NC participants, 0.2 ± 0.5 in MCI, and 0.7 ± 1.4 in AD (p < 0.03 vs NC) and was 6-fold higher in PiB+ than PiB-NC. Incident LMBs were associated with age, APOE ε4+, PiB+, and baseline LMBs. Incidence of multiple LMBs was also associated with lacunar infarction and white matter hyperintensity severity. CONCLUSIONS: Older age, baseline LMBs, higher β-amyloid burden, and concomitant cerebrovascular disease may all confer higher risk of incident LMBs. This should be considered when designing protocols for amyloid-modifying clinical trials.
OBJECTIVE: We sought to determine the incidence and associations of lobar microbleeds (LMBs) in a longitudinal cohort with (11)C-Pittsburgh compound B (PiB) PET imaging. METHODS: One hundred seventy-four participants from the observational Australian Imaging, Biomarkers and Lifestyle Study of Ageing (97 with normal cognition [NC], 37 with mild cognitive impairment [MCI], and 40 with Alzheimer disease [AD] dementia) were assessed at 3 time points over 3 years with 3-tesla susceptibility-weighted MRI and (11)C-PiB PET. MRIs were inspected for microbleeds, siderosis, infarction, and white matter hyperintensity severity, blind to clinical and PiB findings. Neocortical PiB standardized uptake value ratio, normalized to cerebellar cortex, was dichotomized as positive or negative (PiB+/-, standardized uptake value ratio >1.5). Annualized LMB incidence was calculated, and logistic regression was used to determine the association of incident LMBs with PiB, APOE ε4+ status, and cerebrovascular disease. RESULTS: LMBs were present in 18.6% of NC, 24.3% of MCI, and 40% of AD participants (p < 0.05 vs NC). LMB incidence was 0.2 ± 0.6 per year in NC participants, 0.2 ± 0.5 in MCI, and 0.7 ± 1.4 in AD (p < 0.03 vs NC) and was 6-fold higher in PiB+ than PiB-NC. Incident LMBs were associated with age, APOE ε4+, PiB+, and baseline LMBs. Incidence of multiple LMBs was also associated with lacunar infarction and white matter hyperintensity severity. CONCLUSIONS: Older age, baseline LMBs, higher β-amyloid burden, and concomitant cerebrovascular disease may all confer higher risk of incident LMBs. This should be considered when designing protocols for amyloid-modifying clinical trials.
Authors: Cheryl A Hawkes; Maureen Gatherer; Matthew M Sharp; Adrienne Dorr; Ho Ming Yuen; Rajesh Kalaria; Roy O Weller; Roxana O Carare Journal: Aging Cell Date: 2013-02-18 Impact factor: 9.304
Authors: Alex E Roher; Yu-Min Kuo; Chera Esh; Carmen Knebel; Nicole Weiss; Walter Kalback; Dean C Luehrs; Jennifer L Childress; Thomas G Beach; Roy O Weller; Tyler A Kokjohn Journal: Mol Med Date: 2003 Mar-Apr Impact factor: 6.354
Authors: Kejal Kantarci; Jeffrey L Gunter; Nirubol Tosakulwong; Stephen D Weigand; Matthew S Senjem; Ronald C Petersen; Paul S Aisen; William J Jagust; Michael W Weiner; Clifford R Jack Journal: Alzheimers Dement Date: 2013-01-30 Impact factor: 21.566
Authors: Reisa Sperling; Stephen Salloway; David J Brooks; Donatella Tampieri; Jerome Barakos; Nick C Fox; Murray Raskind; Marwan Sabbagh; Lawrence S Honig; Anton P Porsteinsson; Ivan Lieberburg; H Michael Arrighi; Kristen A Morris; Yuan Lu; Enchi Liu; Keith M Gregg; H Robert Brashear; Gene G Kinney; Ronald Black; Michael Grundman Journal: Lancet Neurol Date: 2012-02-03 Impact factor: 44.182
Authors: Jennifer L Whitwell; Kejal Kantarci; Stephen D Weigand; Emily S Lundt; Jeffrey L Gunter; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Anthony J Spychalla; Daniel A Drubach; Ronald C Petersen; Val J Lowe; Clifford R Jack; Keith A Josephs Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472